L19-IL2 reverts radiation-induced lymphopenia in a mouse model of lung cancer
Collectively, utilizing the developed murine RIL models, we observed that RIL did not negatively affect radiotherapy treatment outcome. L19-IL2 can be a promising strategy to restore lymphocyte counts and revert RIL.
Authors
- Lesley Schuitmaker (ORCID: https://orcid.org/0000-0001-9170-6380)
- Èlia Prades-Sagarra (ORCID: https://orcid.org/0000-0003-2834-967X)
- Ala Yaromina (ORCID: https://orcid.org/0000-0002-3900-5314)
- Natasja G. Lieuwes (ORCID: https://orcid.org/0000-0002-9606-0889)
- Rianne Biemans (ORCID: https://orcid.org/0000-0002-9300-0768)
- Nick Staut (ORCID: https://orcid.org/0000-0001-8568-6037)
- Ludwig J. Dubois (ORCID: https://orcid.org/0000-0002-8887-4137)
- Frank Verhaegen (ORCID: https://orcid.org/0000-0001-8470-386X)
- Stefan J. van Hoof
Institutions
- Maastricht University Medical Centre (NL)
- Maastricht University (NL)
- Maastro Clinic (NL)
Publication Details
- Journal
- Radiotherapy and Oncology
- Published
- 2025-04-25
- DOI
- https://doi.org/10.1016/j.radonc.2025.110908
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Maastricht Universitair Medisch Centrum